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Abstract. Pigment epithelium-derived factor (PEDF) is an
endogenous protein factor that has been shown to act as anti-
angiognesis factor. The present study aimed to determine
the direct biological effects of PEDF on lung cancer cells
and deduce a clinical relevance in patients with lung cancer,
major cause of death worldwide in which the knowledge of
PEDF remains poor. We constructed a mammalian expression
system for human PEDF produced recombinant PEDF
(rhPEDF) protein from 3T3 cells. The expression of PEDF
was examined using SDS-PAGE and Western blot analysis.
Using the rhPEDF protein, we investigated the biological
function of PEDF in the lung cancer cells as well as endothelial
cells. PEDF expression levels were assessed in a cohort of
human lung cancer specimen (77 pairs of matched normal
and tumour tissues), in association with patient clinical
variables and survival, using quantitative analysis of PEDF.
In vitro, we found that administration of rhPEDF on two lung
cancer cell lines (A549 and SK-MES1) significantly reduced
tumour cell growth (P<0.05) with no significant effect on the
growth of vascular cell line (HECV). We also found that
rhPEDF significantly decreased lung cancer motility and
adhesion to extracellular matrix (Matrigel) when compared
with the control cells (P<0.05). We showed that reduced
PEDF levels in lung cancer tissues significantly correlated
with lymph node metastasis and an overall poor prognosis
in the lung cancer patients. PEDF suppresses the growth
and motility of lung cancer cells and has a significant
correlation with the clinical outcome of the patients. These
results contribute to our understanding of the molecular
mechanisms of PEDF and indicates a potential prognostic
and therapeutic impact of PEDF in lung cancer.
Introduction
Lung cancer is one of the most prevalence cancers in the
world. About 75% patients have already been found to have
metastatic disease at the time when lung cancer is diagnosed.
The development of metastasis is highly dependent on the
process of angiogenesis. It has been shown indeed that
angiogenesis and angiogenic factors are closely related to
the disease progression in lung cancer. With a growing list
of angiogenic factors being identified in the past decade,
naturally occurring anti-angiogenic factors are rather limited
in their numbers. Pigment epithelium-derived factor, PEDF is
one of the few endogenous anti-angiogenic factors in the body. 
PEDF was first purified from human retinal pigment
epithelial cell conditioned medium with potent neuronal
differentiating activity on retinoblastoma cells (1,2). It is a
secreted glycoprotein of 46 kDa in size and belongs to the
serine protease inhibitor superfamily (3). There are strong
evidence to show that PEDF is an inhibitor of angiogenesis,
the inhibitory effect of which is stronger than that of angio-
statin, thrombospondin-1 and endostatin (4,5). PEDF exerts
the anti-angiogenic activities by inhibiting proliferation and
migration of endothelia cells and induces apoptosis in activated
endothelium. PEDF may restore thrombospondin-1 (TSP-1),
another angiogenesis inhibitor, and modulate vascular forming
(6). PEDF can down-regulate p2(phox) and gp91(phox)
expression and suppress VEGF expression. PEDF can inhibit
the advanced glycation end product (AGE) signalling to
vascular hyperpermeability (7). Collectively, these actions
of PEDF contribute to the anti-angiogenic effect. In clinical
studies, the expression pattern of PEDF has been linked to
a number of pathological conditions in which angiogenesis
is critical. In choroidal neovascularization (CNV) disease,
an ocular angiogenesis disorder, the balance of PEDF and
VEGF expressions is an important contributing factor to the
disease, in that VEGF over-expression facilitates the disease
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development whereas reduced VEGF or enhanced PEDF
expression can have therapeutic effects (8). 
In addition to the potent effect on endothelial cells, PEDF
is also known to act on other cell types. PEDF can stimulate
the pericytes to synthesise platelet-derived growth factor-B
(PDGF-B), a survival factor for pericytes to maintain the
microvascular homeostasis (9). In neonatal astrocytes, PEDF
can induce proinflammatory and immediate-early gene through
the activation of nuclear factor kappa B (NF-κB) or cyclin
AMP-responsive element binding protein (CREB) (10).
PEDF is a multi-potent factor affecting neurons and neonatal
astrocytes. In neurons, expression of pro-survival genes,
including c-IAP1, c-IAP2, FLIPs, A1/Bfl-1 and Mn-SOD,
can be induced by PEDF. Interestingly, the pro-apoptotic
Bcl-2 family members Bax and Bid were not affected by
PEDF (11).
In clinical cancer, PEDF has been found to have a prog-
nostic significance in breast cancer, liver cancer, Wilms'
tumour and indeed in lung cancer (12-14). These studies
have shown that loss/reduced expression of PEDF facilitates
disease progression and results in a poor prognosis in the
patients. It has been suggested that this link to prognosis is
the result of increased angiogenesis in the tumour due to the
loss of anti-angiogenic control by PEDF. However, it has
been recently shown that when engineered to express PEDF,
certain cancer cells, such as prostate cancer, osteosarcoma,
ovarian cancer, pancreatic cancer, malignant glioma, neuro-
blastoma, have a reduced growth rate, thus arguing for a
potential direct effect of PEDF on cancer cells (15-20). 
We recently reported that expression of PEDF in non-small
cell lung cancer is reduced and that the reduction of PEDF
is linked to a poor clinical outcome (14). We have further
shown that forced expression of PEDF in endothelial cells
resulted in reduction of motility and tubule formation (21). In
the present study, we first produced recombinant human
PEDF and then tested the direct biological effect of PEDF on
lung cancer cells. Finally, we have provided first line report
that expression of the PEDF transcripts was linked to the
long-term survival of the patients. 
Materials and methods
Cell lines, materials and human lung specimens. Human lung
cancer cell line A549 (adenoma carcinoma) and SKMES1
(squamous carcinoma), fibroblast cell line NIH 3T3 cell line
and the Chinese Hamster Ovary cell line, CHO cells (American
Type Culture Collection, Manassas, VA) were maintained in
Dulbecco's modified Eagle's medium (DMEM) supplemented
with 10% fetal calf serum (FCS) and antibiotics. HECV
(ICLC HL01001) (human vascular epithelium cell) cell lines
were obtained from Interlab Cell Line Collection (ICLC),
Naples, Italy. The pEF6/v5-his cloning vector was purchased
from Invitrogen (Pasley, Scotland, UK). Goat anti-human
PEDF, mouse anti-human GAPDH antibodies and mouse
anti-His antibody were obtained from Santa Cruz Biotechno-
logy (Santa Cruz, CA). Matrigel (reconstituted basement
membrane) was purchased from Collaborative Research
Product (Bedford, MA, USA). Other kits and reagents were
obtained from Sigma-Aldrich (Poole, UK), unless otherwise
stated.
Fresh frozen lung tissues, 77 pairs of matched normal and
tumour tissues from the same patients were obtained from
patients who attended Beijing Cancer Hospital from January
2004 to August 2007, under ethics committee approval. None
of the patients received any neoadjuvant therapy prior to
surgery. Histological types of the lung cancers are given in
Table I. Clinicopathological characteristics of the tumours were
defined according to the TNM criteria of the UICC (22). These
tissues were collected immediately after surgical resection at
the Beijing Cancer Hospital and were stored in the Tissue
Bank of Peking University Oncology School. Clinicopatho-
logical factors, including age, sex, histological types of tumours,
TNM stage, and lymph node metastasis were recorded and
stored in the patients' database. Patients were followed-up
from the day of operation to August 2008 as the end of the
follow-up for the present study. The follow-up intervals were
calculated as survival intervals after surgery. For clinical data,
see Table I.
Recombinant PEDF protein production with a mammalian
system. We first constructed a mammalian expression system
for human PEDF. The full-length PEDF gene sequence was
amplified by reverse transcription-polymerase chain reaction
(RT-PCR) using the primers listed in Table II. The PCR
products were T-A cloned into a pEF6/v5-His cloning vector
(Invitrogen) which has elongation factor · promoter (EF6), a
blasticidin resistance gene (for mammalian cells) and ampicillin
resistance gene (for prokaryotic cells). The ligated product
was subsequently used to transform the One-Shot E. coli
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Table I. The clinical and pathological characteristics of the
study cohort.
–––––––––––––––––––––––––––––––––––––––––––––––––
Clinical information No.
–––––––––––––––––––––––––––––––––––––––––––––––––
Sex
Male 52
Female 25
Histologic type
Squamous 31
Adenocarcinoma 37
Small cell lung cancer 3
Other type 4
Tumour status
T1-2 51
T3-4 26
Lymph node status
N0-N1 52
N2 25
TNM stage
I-II 32
III 35
–––––––––––––––––––––––––––––––––––––––––––––––––
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(Invitrogen). Following selection of strains, which has full-
length PEDF cDNA correctly inserted, E. coli was scaled
up to allow amplification of the plasmid. Plasmids were
extracted, purified, and used to transfect 3T3 cell line with
an Easyject Plus electroporator (EquiBio, Kent, UK). After
up to 2 weeks of selection with Blasticidin (5 μg/ml), the
transfectants were grown to sufficient number and used in the
current study.
RNA preparation and analysis of gene transcript by RT-PCR.
RNA was obtained using Total RNA Isolation Reagent
(ABgene™). RNA (0.25 μg) was used to produce the first
strand cDNA using a Reverse transcription kit (Sigma,
Poole, Dorset, UK). PCR was undertaken using a REDTaq™
ReadyMix PCR reaction mix (Sigma-Aldrich, Inc.). Cycling
conditions for the reaction were 94˚C for 5 min, followed by
40 cycles of 94˚C for 30 sec, 58˚C for 30 sec, and 72˚C for
40 sec. This was followed by a final extension of 10 min at
72˚C. The quality of cDNA was verified by 532-bp GAPDH
PCR product with the anneal temperature of 55˚C (primers
for PEDF and GAPDH were listed in Table II). Products
were separated by 2% agarose gel and stained with ethidium
bromide, visualizing under UV light.
SDS-PAGE and Western blotting to test the expression
situation of PEDF plasmid. Cells were pelleted and protein
extracted in HCMF buffer (160 mM NaCl, 0.6 mM Na2HPO4,
0.1% w/v glucose and 0.01 M HEPES, pH 7.4) containing
0.5% Triton X-100, 2 mM CaCl2, 100 μg/ml phenylmethyl-
sulfonyl fluoride, 1 μg/ml leupeptin, and 1 μg/ml aprotinin
for 30 min. They were clarified at 13,000 x g for 15 min.
Protein concentrations were measured using fluorescamine
and quantified by using a multifluoroscanner (Denly, Sussex,
UK). Equal amounts of protein from each cell sample were
denatured in a sample buffer and boiled for 5 min, before
separated on a 10% (for PEDF and GAPDH) polyacrylamide
gel. Following electrophoresis, proteins were blotted onto
nitrocellulose sheets and blocked in 10% skimmed milk (w/v
in TBS) for 1 h before probing with the appropriate antibody.
The membrane was probed with peroxidase-conjugated
secondary antibody (1:1000). Protein bands were visualised
with the ECL system (Amersham, UK). The band densities
on the photographic film were analyzed with a UVI tech
imager (UVI TECH, Cambridge, UK) and are shown as
relative values.
Preparation of recombinant human rhPEDF protein from
the condition medium of 3T3 cell transfected with PEDF
expression construct. Conditioned media from 3T3 cells,
transfected with the PEDF expression vector, and containing
rhPEDF were collected from roller bottles. PEDF proteins
were purified from the conditioned media by Ni-NTA heavy
metal Affinity columns (Amersham Biosciences AB,
Sweden) according to the manufacturer's instructions. A
binding buffer (8X PBS 3 ml; 2 mmol/l Imidazole 0.12 ml;
H2O to 24 ml; pH 7.4-7.6) and an elution buffer (8X PBS 3 ml;
Iimidazole (2, 1, 0.5, 0.25 and 0.125 mmol/l) 2 ml; H2O to
8 ml; pH 7.4-7.6) were used for preparing the column and
for elution of recombinant proteins. The final concentration
of Imidazole in the elution buffer was 500, 250, 125, 62.5
and  31.3 mM. After initial washing, the columns were charged
with 0.5 ml of 0.1 M NiSO4. This was followed by adding
binding buffer, loading samples, washing the columns and
eluting rhPEDF with elution buffer. The presence and the
purity of rhPEDF were verified using Western blotting with
anti-His and anti-PEDF antibodies. Protein concentration was
calculated using a BioRad DC protein assay kit (Bio-Rad
Laboratories, Hercules, CA).
In vitro cell growth assay. This was based on a previously
reported method (23). Cells were plated into a 96-well plate
at 2,000 cells/well after a period of incubation. SkMes1,
A549 lung cancer cells and HECV cells were treated with or
without various concentration of rhPEDF. Cells were fixed in
10% formaldehyde on the day of plating and daily for the
subsequent days, 0.5% crystal violet (w/v) was used to stain
the cells. Following washing, the stained crystal violet was
dissolved with 10% (v/v) acetic acid and the absorbance
was determined at a wavelength of 540 nm using an ELx800
spectrophotometer. Absorbance represents the cell number.
Cell-matrix adhesion assay. This was based on a method we
previously reported (24). The 96-well plate was coated with
5 μg of Matrigel and allowed to dry. Following rehydration,
40,000 cells were added to each well. After 40 min of incu-
bation non-adherent cells were washed off using BSS buffer.
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Table II. Primer sequences.
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
Full length PEDF Forward GACATGCAGGCCCTGGT
Reverse GGGGCCCCTGGGGTCCAGAA
PEDF Forward CGATGAGATCAGCATTCTCC
Reverse ATTCTGGGTCACTTTCAGGG
GAPDH Forward AGGTCGGAGTCAACGGATTTG
Reverse GTGATGGCATGGACTGTGGT
PEDF qPCR Forward GGTGCTACTCCTCTGCATT
Reverse ACTGAACCTGACCGTACAAGAAAGGATCCTCCTCCTC
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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The remaining cells were fixed with 4% formalin and stained
with 0.5% crystal violet. The number of adherent cells was
then counted under microscopy.
In vitro motility assay using cytodex-2 beads. We followed
the protocol described by Rosen et al (25). Cells (1x106)
were incubated with 100 μl Cytodex-2 beads (Pharmacia,
Piscataway, NJ) in 10 ml DMEM medium overnight to allow
cells to adhere to the cytodex-2 beads. After the medium was
aspirated and the beads were washed with DMEM, they were
aliquated into wells of a 24-well plate (100 μl/well). After 4 h
of incubation, the beads were washed off. The cells that
migrated onto the bottom of each well were fixed with 4%
formalin for 5 min and were stained with 0.5% crystal violet.
The cells were counted under a microscope. The experiment
was performed three times.
PEDF expression level in lung cancer and normal lung tissue
assessed by real-time RT-PCR. Level of PEDF transcript from
the above prepared cDNA was determined using real-time
quantitative PCR based on the AmplifluorTM technology,
modified from a method reported previously (26). PCR primers
were designed using Beacon Design software (Biosoft
International, Palo Alto, CA, USA), but to the reverse primer
an additional sequence, known as the Z sequence (5'-actg
aacctgaccgtaca-3') which is complementary to the universal
Z probe (Intergen Inc., Oxford, UK) was added. Primers for
PEDF quantitation are listed in Table II. The reaction was
carried out using the following condition: Hot-start Q-master
mix (Abgene), 10 pmol of specific forward primer, 1 pmol
reverse primer which has the Z sequence, 10 pmol of FAM
tagged probe (Intergen Inc. Oxford, UK) and cDNA. The
reaction was carried out using the IcyclerIQ (Bio-Rad, Hemel
Hemstead, UK) which is equipped with an optic unit that
allows real-time detection of 96 reactions under the following
conditions: 94˚C for 12 min and 65 cycles of 94˚C for 15 sec,
55˚C for 60 sec and 72˚C for 20 sec. The level of PEDF
transcript was generated from a standard that was simulta-
neously amplified with the samples. Expression level of
PEDF gene was then normalized against actin expression
already measured in these specimens, to correct for varying
amounts of epithelial tissue between samples (26).
Statistical analysis. Minitab®, version 14 was used for
analysis. Non-normally distributed data were assessed using
the Mann-Whitney U test, and the 2 sample t-test was used
for normally distributed data. Differences were considered
statistically significant at P<0.05. Survival curve was con-
structed using the Kaplan-Meier method (SPSS version
12.0.0).
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Figure 1. Establishment of 3T3 cells and CHO cells for expressing PEDF (A) and purification of rhPEDF using metal chelating chromatography (B). A, 3T3
cells and CHO cells successfully expressed human PEDF transcripts after transfection. B, Purified rhPEDF protein from condition medium of 3T3 cells.
Shown are the test conditions for eluting the recombinant protein from the Nickel chelating chromatography column. Using the elution buffer with 125 mM
imidazole, we obtained purified rhPEDF protein from the condition medium testing with the anti-PEDF and anti-His antibody.
Figure 2. Effect of PEDF on cell biological behaviour of SKMES1 and
A549 cells. A, PEDF significantly suppressed SKMES1 and A549 lung
cancer cell-matrix adhesion compared to the control cells. B, PEDF
significantly suppressed SKMES1 and A549 lung cancer cell invasion
(P<0.05) compared to the control cells. Asterisk indicates P<0.05.
159-166.qxd  29/5/2009  01:13 ÌÌ  ™ÂÏ›‰·162
Results
Over-expression of PEDF and preparation of rhPEDF. Both
3T3 cells and CHO cells were transfected with PEDF
expression construct and successfully expressed PEDF tran-
script as shown by RT-PCR (Fig. 1A). Direct DNA sequencing
of the PCR product confirmed that the transcript from the
transfected cells was PEDF. Subsequent analysis has shown
that 3T3 secreted rhPEDF more efficiently than CHO cells.
3T3 cells were therefore chosen as the source of recombinant
PEDF. Western blot analysis showed 3T3 cell transfect
with the PEDF plasmid could over-express PEDF protein
(Fig. 1). rhPEDF thus generated displayed a single band with
a molecular weight of ~46 kDa. As showed in Fig. 1B, 125 mM
Imidazole in the elution buffer was the optimal condition
and was used in the present study. Sodium dodecyl sulphate-
polyacrylamide gel electrophoresis analysis of purified PEDF
proteins, with anti-PEDF and anti-His antibody, revealed a
single band with a molecular weight of ~46 kDa, which
showed reactivity with the human PEDF antibody (Fig. 1B).
Effect of rhPEDF on lung cancer cell adhesion and
motility in vitro. When treated with rhPEDF, lung cancer cell
lines, SKMES1 and A549, displayed significant changes in
cellular motility and cell-matrix adhesion compared with the
cancer cells without rhPEDF protein. rhPEDF inhibited
lung cancer cell matrix adhesion, using the in vitro cell
matrix adhesion technique. The number of adherent cells for
the SKMES1 cells treated with rhPEDF were 36.78±5.93
compared with the cells not treated with rhPEDF (58.56±7.90)
(P<0.05, Fig. 3A). The number of adherent cells for the
A549 cells treated with rhPEDF were 33.78±4.29 compared
with the cells not treated with rhPEDF (57.56±9.10) (P<0.05,
Fig. 2A). 
rhPEDF also significantly reduced the motility of SKMES1
and A549 cells. The number of migrating SKMES1 cells
treated with rhPEDF was 15.8±6.09 compared with 28.6±10.66
for SKMES1 without rhPEDF (Fig. 3B). The number of
migrating A549 cells treated with rhPEDF was 12±4.49 com-
pared with 24.4±5.78 for A549 without rhPEDF (Fig. 2B).
PEDF inhibited the growth of lung cancer cells in vitro, with
little impact on the growth of vascular cells. We firstly
evaluated the anti-proliferative effect of rhPEDF treatment on
human vascular cell line (HECV) and two lung cancer cell
lines, SKMES1 and A549 cell lines. All cell lines were treated
with increasing concentration of rhPEDF (5, 10, 50, 100, 200
and 400 ng/ml) over a 4-day period, with culture medium as
a control. On HECV cells, rhPEDF had no significant effect
on the growth except that at a concentration of 100 ng/ml,
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Figure 3. Effect of different concentrations of PEDF on the growth of HECV and lung cancer cells in vitro. A, HECV cells; B, SKMES1 cells; C, A549 lung
cancer cells. Left panel, 0 days; right panel, 3 days. Exogenous PEDF protein significantly reduced the growth of both lung cancer cells at concentrations
>10 ng/ml. However, rhPEDF only affected the growth of HECV cells at a higher concentration.
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rhPEDF reduced the growth (P=0.041) (Fig. 3A). However,
in both SKMES1 and A549 cells, a statistically significant
dose-dependent reduction in cell proliferation was observed
(Fig 3B and C). In SKMES1 cells, after 3-day treatment with
rhPEDF resulted in an 8.39% (5 ng/ml) (P=0.144), 21.35%
(10 ng/ml) (P=0.006), 29.32% (50 ng/ml) (P=0.027), 51.7%
(100 ng/ml) (P<0.001), 70.81% (200 ng/ml) (P<0.001),
78.68% (400 ng/ml) (P<0.001) reduction in cell numbers
compared to control (Fig. 3B). In A549 cells, a similar effect
on cell proliferation was also seen with rhPEDF (Fig. 3C).
In A549 cells, after 3-day treatment with rhPEDF resulted
in a 6.6% (5 ng/ml) (P=0.05), 12.96% (10 ng/ml) (P=0.014),
21.44% (50 ng/ml) (P<0.001), 37.14% (100 ng/ml) (P=0.001),
40.48% (200 ng/ml) (P<0.001), 45.75% (400 ng/ml) (P<0.001)
reduction in cell numbers compared to control. As shown
in Fig. 4A, A549 cells treated with rhPEDF showed a
significant decrease in growth rate compared with A549
control cells on the second day (P=0.007) and the fourth day
(P=0.014). SKEMS1 cells treated with rhPEDF also showed
a significant decrease in growth compared with the wild-type
control cells on the first day (P=0.001), second day (P=0.005),
third day (P=0.011) and the fourth day (P<0.001) (Fig. 4B).
The clinical analysis of PEDF gene expression in lung cancer.
We quantified the PEDF transcripts in lung cancer specimens
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Figure 4. Time course of rhPEDF induced growth inhibition of SKMES1
and A549 were inhibited with rhPEDF protein. Shown are the percentage
reduction of the growth of the cells. rhPEDF significantly inhibited the
growth after 2-day treatment.
Figure 5. Quantitative PCR analysis of PEDF expression in human lung
cancer tissue. A, The level of PEDF expression from patients in cancer tissue
was significantly lower than the PEDF level in normal tissue (P=0.007). B,
Patients with lymph node distant metastasis (N2) have significantly reduced
levels of PEDF expressed in their tumours compared with the tumours of
patients with no lymph node distant metastasis (N0+N1) (P=0.048). C,
Patients with local advanced stage (stage III) have reduced levels of PEDF
expressed in their tumours compared with the tumours of patients with early
stage (stages I+II), but it is not significant (P=0.409).
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(tumour, n=77; matched paired tissue, n=77) using real-time
quantitative PCR (all values are displayed as mean PEDF
transcript copies/μl). We report that normal lung tissues had
significantly higher levels of PEDF transcript than tumour
tissues (84875.6±455956.47 copies/μl for normal tissues vs.
14029.43±79922.47 for tumour tissues, P=0.007, Fig. 5A).
PEDF expression levels were assessed in relation to lymph
node metastasis status (N0+N1, n=52; N2, n=25) and tumour
TNM stage (I+II stage, n=42; III stage, n=35). The tumours
with distant lymph node metastasis (N2) (248.96±181.58
copies/μl) had significantly reduced levels of PEDF compared
with tumours with no distant lymph node metastasis (N0+N1)
(20654.66±13431.13 copies/μl) (P=0.048) (Fig. 5B). We
also analyzed PEDF expression in relation with the TNM
staging of the tumours. We showed that PEDF levels were
reduced in patients with stage III (9722.854±6511.963 copies/
μl) compared with the early stage (I+II stage) patients
(17618.24±15871.96 copies/μl) (Fig. 5C). Although it was
not statistically significant (P=0.409). After 48 months of
follow-up, patients were analyzed for survival time based on
PEDF expression level. The mean time of follow-up for
the cohort (n=77) was 19.46 months (range 1-48 months).
The mean (SD) survival time was 19.46±10.18 months.
Cumulative survival curves were calculated using the Kaplan-
Meier method. In the patients with high level expression of
PEDF there was almost no deaths during the follow-up time
of 36 months. In the patients with low expression level of
PEDF the mean survival time was 34.63 months (95%CI:
27.87-41.40). The levels of PEDF mRNA expression were
negatively correlated with cumulative survival time. Patients
with high level of PEDF had significantly longer survival
time than the patients with low level of PEDF (P=0.0459,
Fig. 6).
Discussion
PEDF is one of the most potent anti-angiogenic factors, and
is a pleiotropic factor initially identified as a neurotrophin (2).
The factor has been shown to have a strong anti-angiogenic
effect, in vitro and, in clinical studies, has an aberrant pattern
of expression. In the present study, we have provided evidence
that PEDF has a direct effect on lung cancer cells.
It has been reported that PEDF can dramatically suppress
primary osteosarcoma and prevent development of macro-
scopic pulmonary metastases in vivo (19). Loss of PEDF
expression was found in human prostate tumours and
associated with the progression toward a metastatic
phenotype, and microarray analysis showed over-expression
of PEDF in prostate cancer cell associated with cell
functional activites, such as protein binding, signal
transduction activity and cell invasion (20). Our previous
study showed that PEDF was also expressed in lung cancer
tissue (14). The present study first sought to demonstrate the
direct biological function of PEDF in lung cancer and has
shown that exogenous rhPEDF had a marked inhibitory effect
on cellular motility and adhesion of human lung cancer cells.
It is interesting to note that the inhibitory effects of rhPEDF
on lung cancer cells was more effective and sensitive than
that seen on endothelial cells. In view of our data, we suggest
that PEDF has an important role in controlling the invasiveness
and migration of lung cancer cells.
Although PEDF has been shown to inhibit tumour-induced
angiogenesis (27), our present study shows that rhPEDF
exerts an inhibitory effect on the growth of vascular cells
only at much higher concentrations (>100 ng/ml). Collectively,
it suggests that PEDF influences angiogenesis through
affecting the angiogenesis process without significantly
affecting the proliferation of vascular endothelial cells. 
The impact of PEDF in cancer has been reported in recent
years. PEDF has been shown to have a potential function
to inhibit cancer, including osteosarcoma, ovarian carcinoma
and prostate cancer (18-20). Our previous study showed that
high levels of PEDF expression in lung cancer tissue were
correlated with patients prognosis and that PEDF was an
important factor in lung cancer development (14). However,
there has been no studies whether PEDF protein has a direct
influence on the growth of lung cancer cells. With two human
lung cancer cell lines, our tests showed PEDF can significantly
inhibit cell growth (Figs. 3B and C and 4). Collectively,
PEDF has a direct effect on the biological behaviour of lung
cancer cells. Together with its potential anti-angiogenic effect,
PEDF does indeed have a potential value in cancer treatment.
The potential clinical value of PEDF in lung cancer is
further reflected in our clinical studies, in which we used
real-time PCR to measure PEDF expression level in lung
tissue and analysed the correlation with the clinicopathological
data. The present study is the first to use a large cohort of
lung tissue samples to determine the range and level of
PEDF in lung cancer and report that in human lung cancer,
transcript levels of PEDF are lower than that in normal tissues
(Fig. 5A). Loss of PEDF expression may have a role in the
process of lung cancer development. PEDF gene expression
level has a relationship with the lymph node metastasis in
lung cancer patients (Fig. 5B). Moreover, high levels of
INTERNATIONAL JOURNAL OF ONCOLOGY  35:  159-166,  2009 165
Figure 6. Kaplan-Meier analysis of overall survival of lung cancer patients
depending on the expression level of PEDF mRNA. High level of PEDF
was associated with significantly longer survival compared with those who
had low level (P=0.0459).
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PEDF were not significantly correlated with TNM stage
(Fig. 5C). Our previous study using SYFRE GREEN method
to test PEDF expression level in 21 NSCLC samples showed
that PEDF level was significantly lower than the normal
tissue (14). Low levels of PEDF have been previously
reported in breast cancer and glioma (28,29). Taken together,
we can conclude that PEDF may be a protective factor for
patients with lung cancer and it has an important role to play
in lymph node metastasis from lung cancer.
In conclusion, PEDF is a potent lung cancer suppressor
and is associated with the long-term survival of the patients.
PEDF has multifunctional activity in inhibiting lung cancer
growth and preventing tumour cell motility, making it a
potential candidate for targeted anticancer therapeutics.
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